Last updated: July 30, 2025
Introduction
The patent KR102212275, granted in South Korea, pertains to a novel pharmaceutical invention aimed at addressing specific therapeutic or manufacturing challenges within the pharmaceutical sector. An in-depth understanding of this patent’s scope, claims, and its position within the patent landscape informs stakeholders—ranging from biopharmaceutical companies to patent attorneys—about its competitive significance, enforceability, and potential for innovation.
Scope of Patent KR102212275
KR102212275 is a patent classified under the Korean Intellectual Property Office (KIPO) classification system, likely within domains such as pharmaceutical compositions, formulations, or drug delivery systems. The scope encompasses the core inventive concept, which can be broadly defined as a specific chemical entity, formulation, process, or combination aimed at improving the efficacy, stability, or manufacturing process of a therapeutic agent.
The scope typically includes:
- Compound-specific features: Chemical structures, stereochemistry, or modifications.
- Formulation and delivery: Modes of administration, excipients, or controlled-release features.
- Manufacturing methods: Novel synthesis routes or purification techniques.
- Therapeutic indications: Specific diseases or conditions targeted by the invention.
Given the trend in pharmaceutical patents, the scope likely emphasizes a novel compound or a specific formulation with improved bioavailability, reduced side effects, or resistance mitigation.
Claims Analysis
The scope of a patent is fundamentally determined by its claims, which define the legal boundaries of the invention.
Types of claims:
- Independent claims: Broadest assertions covering the core invention, e.g., a compound or a formulation with specified features.
- Dependent claims: More specific features, such as specific substituents, dosage forms, or manufacturing processes.
Typical claim structure for KR102212275:
- Claim 1: Usually an independent claim, perhaps describing a pharmaceutical compound with a specific chemical backbone or a formulation comprising the compound and an excipient.
- Claims 2-10: Often dependent, detailing particular embodiments—such as salt forms, polymorphs, or process steps.
Key features likely covered:
- Innovation over prior art in chemical structure or formulation.
- Specific methods of synthesis or preparation.
- Targeted therapeutic uses, e.g., treatment of cancer, infectious diseases, or neurological disorders.
- Delivery system characteristics, such as nanoparticles or controlled-release matrices.
Patentees often aim to craft claims that balance broad protection with enforceability, capturing core inventive aspects while avoiding overreach that could be invalidated.
Patent Landscape and Competitive Context
1. Patent Family and Priority Documents:
- KR102212275 may form part of a broader patent family, indicating international filing strategies—possibly including WO (worldwide), US, and Chinese patents.
- Its priority date influences the scope of prior art considerations. An earlier priority date generally expands protection and reduces validity challenges.
2. Prior Art and Patent Novelty:
- The patent's novelty hinges on differentiating features from existing compounds and formulations. KR patent examiners consider prior art databases, including international patent collections and scientific literature.
- Similar patents include those that cover related chemical classes or similar formulations, potentially limiting scope or creating overlap.
3. Patent Thickets and Landscape:
- The pharmaceutical landscape often involves complex patent thickets, where overlapping rights from different patents can create free zones or blockades.
- KR102212275 may intersect with patents covering similar chemical scaffolds, delivery systems, or medical indications. Its enforceability depends on the specificity and territorial scope.
4. Competitor Patent Strategies:
- Competitor filings in East Asia, particularly China and Japan, may influence the patent’s commercial value.
- Patent filings in high-value markets like the US or Europe could enhance its global strategic importance.
Legal and Commercial Implications
Validity and Enforceability:
- Given Korea’s robust patent examination procedures, the claims likely possess a high degree of validity if adequately supported by data.
- However, competitors may challenge the patent based on obviousness or lack of inventive step, especially if similar compounds or formulations are documented in prior art.
Freedom to Operate (FTO):
- Firms interested in commercializing drugs covered by KR102212275 must analyze overlapping patents for potential infringement risks.
- Licensing or design-arounds may be necessary if competing patents challenge or limit the scope of this patent.
Lifecycle and Market Strategy:
- The patent’s expiration date—typically 20 years from filing—dictates the window of exclusivity.
- Strategies may include complementary patents on supplementary formulations or methods to extend commercial protection.
Conclusion
KR102212275 manifests a strategic innovation within South Korea’s vibrant pharmaceutical patent landscape. Its scope appears focused on novel compounds or formulations tailored for enhanced therapeutic efficacy, with claims carefully crafted to minimize invalidation risks. The patent contributes to the competitive fabric that sustains innovation, although enforced protection depends on its novelty over prior art and the strength of its claims.
Key Takeaways
- The scope of KR102212275 likely covers specific chemical entities or formulations with potential therapeutic advantages, essential for market exclusivity.
- Effective claims drafting involves balancing breadth with enforceability, focusing on core inventive features.
- The patent landscape in South Korea encompasses a competitive environment featuring overlapping patents—necessitating strategic FTO analyses.
- Firms should monitor prior art and competitor filings to mitigate infringement risks and leverage this patent for licensing or partnership opportunities.
- Remaining aware of patent expiration and potential patent extensions informs long-term commercialization planning.
FAQs
1. What is the priority date of KR102212275, and why does it matter?
The priority date indicates when the invention was first disclosed or filed. It determines novelty over prior art and impacts patent term, influencing exclusivity duration.
2. How broad are the claims likely to be in KR102212275?
While specific claim language drives scope, Korean patents typically aim for a balance—covering core innovative elements while avoiding overreach that invites invalidation.
3. Can this patent be challenged or invalidated?
Yes. Competitors may challenge based on prior art, obviousness, or lack of inventive step. The validity depends on patent prosecution quality and subsequent legal defenses.
4. How does KR102212275 compare to similar patents globally?
It depends on the specific claims and filing strategies. As part of an international portfolio, it may be complemented by patents filed in other jurisdictions for broader protection.
5. What are the strategic considerations for a pharmaceutical company regarding KR102212275?
They must assess infringement risks, opportunities for licensing, and potential for developing improved or related formulations—aligning with their broader R&D and commercialization goals.
References
[1] Korean Intellectual Property Office (KIPO) Patent Database, Patent KR102212275.
[2] WIPO Patent Family Reports and International Filing Status.
[3] Roche and GSK patent strategies in pharmaceutical innovations (industry reports).
